[Gene expressions of xylosyltransferase and heparanase in renal tissue of rat with adriamycin nephropathy and relevance for proteinuria].
OBJECTIVE
To evaluate the roles of P-D-xylosyltransferase I (XT-I) and beta-D-endoglycosidase heparanase (Hpa) in renal tissue with the development of adriamycin (ADR) nephropathy and relevance for proteinuria.


METHODS
150-200 g Sprague-Dawley rats (n=10 per group) were used to make the nephropathy model induced by tail intravenous injection of 6 mg/kg ADR. Rats were housed in metabolic cage for 24 hours so as to collect the urine prior to disease induced and at day 7, 14 and 21 following disease induction. By using the method of reverse transcriptase-PCR (RT-PCR), XT- I and Hpa genes from renal tissue of these groups were assayed respectively.


RESULTS
(1) Rats with nephropathy at day 7, 14 and 21 showed the marked up-regulated XT- I mRNA and the significant difference in contrast to the normal rats,and rats at day 21 showed the marked up-regulated XT- I mRNA and significant difference in contrast to nephropathy rats at day 7. There was a positive linear correlation between the expression level of XT- I mRNA from the renal tissue of nephropathy rats and the quantity of urinary protein (r = 0.760, P < 0.05). (2) The nephropathy rats at day 7, 14 and 21 showed marked up-regulated Hpa mRNA and significant difference in contrast to the normal rats,the rats at day 14 and 21 showed marked up-regulated Hpa mRNA and significant difference in contrast to the rats at day 7. There was a positive linear correlation between the expression level of Hpa mRNA from renal tissue and quantity of rat urinary protein (r = 0.757, P < 0.05).


CONCLUSIONS
The up-regulated expressions of XT- I and Hpa mRNA in rat renal tissue exist in Adriamycin nephropathy. Higher Hpa mRNA expression, more quantity of urinary protein;more quantity of urinary protein,higher XT-I mRNA expression.
Luo
Wei
W
Chengdu Children's Hospital, Chengdu 610017, China.
Wang
Zheng
Z
D000818:Animals; D004317:Doxorubicin / Q000009:adverse effects; D015870:Gene Expression; D005966:Glucuronidase / Q000378:metabolism*; D007668:Kidney / Q000378:metabolism / Q000473:pathology; D007674:Kidney Diseases / Q000139:chemically induced / Q000235:genetics*; D010430:Pentosyltransferases / Q000378:metabolism*; D011507:Proteinuria / Q000235:genetics*; D051381:Rats; D017207:Rats, Sprague-Dawley; D000097608:UDP Xylose-Protein Xylosyltransferase; D000099175:Heparanase
D004317:Doxorubicin; D005966:Glucuronidase; D010430:Pentosyltransferases; D000097608:UDP Xylose-Protein Xylosyltransferase; D000099175:Heparanase